Reading IRD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IRD free→Reading IRD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IRD free→QuarterlyIQ Insights · IRD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agreement (the “Note Purchase Agreement”) with OPCM SA LLC, as purchaser agent, and certain purchasers party thereto (the “Purchasers”). The Note Purchase Agreement provides for, among ot…
Entry into a Material Definitive Agreement. Note Purchase Agreement On April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agreement (the “Note Purchase Agreement”) with OPCM SA LLC, as purchaser agent (“Purchaser Agent”), and certain purchasers party thereto (the “Purchasers”). Capitalized terms used but not defined herein have the meanings given to such terms in the Note Purcha…
Unregistered Sales of Equity Securities. The information set forth in
and in Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements wit…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2026, Opus Genetics, Inc. (the “Company”) entered into a Change in Control Bonus Payment Agreement with each of Dr. George Magrath, Robert Gagnon, Joseph Schachle, and Dr. Ashwath Jayagopal, its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Scientific and Development Officer, respectively (the “Exec…
of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement. Private Placement On February 13, 2026, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) for a private placement (the “Private Placement”) of an aggregate of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Series B Preferred Stock is being issued to…
Results of Operations and Financial Condition. On February 13, 2026, the Company issued a press release regarding the Private Placement. The press release presented a pro forma cash balance of the Company of $70 million as of December 31, 2025, after giving effect to the proceeds of the Private Placement. The Company’s preliminary cash balance as of December 31, 2025 is $45 million. Because the Company’s financial statements for the year ended December 31, 2025 have not yet been finalized, th…
of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. Registered Direct Offering On November 5, 2025, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain affiliates of Perceptive Advisors LLC, Nantahala Capital Management, LLC and Balyasny Asset Management L.P. (collectively, the “ Purchasers ”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “ Offering ”), an aggregate of (i) 3,827,751…
Other Events. The Company reported positive data from the OPGx-LCA5-1001 Trial evaluating OPGx-LCA5. OPGx-LCA5 has been well tolerated in all six participants treated to date (three adults and three pediatric participants), with no ocular serious adverse events or dose-limiting toxicities observed. All ocular adverse events were mild in severity and anticipated, with no events related to the study drug. One pediatric participant had a pre-existing cataract that worsened at three months, attri…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 29, 2025, Opus Genetics, Inc., a Delaware corporation (the “ Company ”), appointed Robert Gagnon as the Company’s Chief Financial Officer and principal accounting officer, effective September 2, 2025 (the “ Effective Date ”). In connection with his appointment, on August 29, 2025, Mr. Gagnon entered into an employment agreement (the “ Emp…
Unregistered Sale of Equity Securities. On August 25, 2025, Opus Genetics, Inc., a Delaware corporation (the “ Company ”), entered into subscription agreements (the “ Subscription Agreements ”) pursuant to which the Company agreed to issue and sell in a private placement (the “ Private Placement ”) to certain investors (the “ Subscribers ”) an aggregate of 3,138,338 shares (the “ Shares ”) of its common stock, par value $0.0001 per share (the “ Common Stock ”). The aggregate gross proceeds fr…
of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. On July 22, 2025, Opus Genetics, Inc., together with its wholly owned subsidiary, OpusTX, LLC (collectively, the “ Company ”), entered into a funding and license agreement (the “ Agreement ”) with Eyes on the Future (“ EOTF ”), and RDH12 Fund for Sight (the “ Fund ,” and together with EOTF, the “ Funding Parties ”), relating to the Company’s program to develop gene therapies that treat patients with inherited retinal degeneration associated with mut…
Other Events VEGA-3 Phase 3 Trial Topline Results On June 26, 2025, Opus Genetics, Inc. (the “ Company ”) announced topline results from VEGA-3, its second pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein. As announced in the press release, the Company is hosting a webcast and conference call this morning at 8:00 a.m. Eastern Time to discuss recent c…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 25, 2025, Nirav Jhaveri, the Chief Financial Officer of Opus Genetics, Inc., a Delaware corporation (the “ Company ”), departed from the Company. Mr. Jhaveri’s departure was due to a termination without cause and was not the result of any disagreement with the Company’s independent auditors or any member of management on any matter of accou…
Entry into a Material Definitive Agreement. On June 13, 2025, Opus Genetics, Inc. (the “ Company ”) entered into a funding agreement (the “ Agreement ”) with the Foundation Fighting Blindness Retinal Degeneration Fund (“ RDF ”), whose sole member is Foundation Fighting Blindness, a significant stockholder of the Company, relating to the Company’s program to develop gene therapies to treat patients impacted by retinitis pigmentosa caused by pathogenic variants in the Mer proto-oncogene tyrosin…
of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Termination of a Material Definitive Agreement. On April 2, 2025, Opus Genetics, Inc., a Delaware corporation (the “ Company ”), delivered written notice to Lincoln Park, Capital, LLC of its election to terminate that certain Purchase Agreement (the “ Purchase Agreement ”), dated as of August 10, 2023, by and between the Company and Lincoln Park Capital Fund, LLC, an institutional investor (“ Lincoln Park ”), effective as of April 3, 2025. The Purchase Agreement provided the Company with the…
of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Unregistered Sales of Equity Securities. On March 21, 2025, Opus Genetics, Inc., a Delaware corporation (the “Company”), entered into a subscription agreement with Dr. George Magrath, the Company’s Chief Executive Officer, and Cam Gallagher, the chairman of the Company’s board of directors, (the “Subscription Agreement”) for the issuance and sale by the Company of 1,176,471 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and warrants to purchase 1,176,471 s…
Results of Operations and Financial Condition. On March 20, 2025, Opus Genetics, Inc., a Delaware corporation (the “Company”), disclosed that it expects: • a net loss for the year ended December 31, 2024 of approximately $56.8 million; • net cash used in operating activities for the year ended December 31, 2024 to be approximately $25.6 million; and • a cash and cash equivalents balance of approximately $30.3 million as of December 31, 2024. Because the Company’s consolidated financial statem…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.